| 2018-10-19 17:57:33|
REGN, SNY 17:57 10/19 10/19/18
Regeneron, Sanofi: FDA approves asthma indication for Dupixent
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced the U.S. FDA has approved Dupixent as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 and interleukin-13, two key proteins that contribute to the Type 2 inflammation that may underlie moderate-to-severe asthma. This effect is associated with the reduction of inflammatory biomarkers including fractional exhaled nitric oxide, immunoglobulin E and eotaxin-3.